Meeting expected to occur approximately 30 days from the FDA's receipt of meeting request PRINCETON, N.J., April 24, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced… Read More..

Clinical study will evaluate safety and tolerability of Lexaria's patented DehydraTECH-CBD as a potential treatment for hypertension California-based InClin to provide CRO services to manage and expedite the study Lexaria is working with its regulatory and clinical advisors toward upcoming IND submission KELOWNA, BC / ACCESSWIRE / April 24, 2023… Read More..

Lead therapeutic candidate for Alzheimer’s disease, PMN310, demonstratedselective binding and protection against toxic amyloid-beta oligomers Preclinical data support misfolded RACK1 as a potential target for ALS and FTLD-TDP TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 24, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused… Read More..